1. Chimeric antigen receptor T-cell therapy for solid tumors
Kheng Newick, Edmund Moon, Steven M Albelda 
Molecular Therapy - Oncolytics 
Volume 3, (January 2016)
DOI: /mto
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

2. Figure 1
Building blocks of chimeric antigen receptor (CAR) T cell. The single chain (scFv) targeting moiety is taken from the antigen-binding domain of antibodies, fused to the CD3ζ transmembrane and intracellular signaling domains from the T-cell receptor complex; this is the first-generation CAR. Later, additional intracellular signaling domains were added for costimulatory signals, such as the CD28 and 41BB signaling domains, to yield second- and third-generation CARs.
Molecular Therapy - Oncolytics 2016 3, DOI: ( /mto )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

3. Figure 2
Immunosuppressive tumor microenvironment. This diagram represents a simplified schema of the negative elements that barrage activated chimeric antigen receptor T cells as they navigate through the tumor landscape, thereby inactivating them. These barriers in solid tumors rapidly neutralize the antitumor effect.
Molecular Therapy - Oncolytics 2016 3, DOI: ( /mto )
Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions